Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR): A Randomized Multi-center Study for Men With Newly Diagnosed Favorable Risk Prostate Cancer
Condition: Prostate Cancer
Study Type: Interventional
Clinical Trials Identifier NCT 8-digits: NCT04396808
Sponsor: University of Michigan Rogel Cancer Center
Eligibility:
- Age: minimum 18 Years maximum N/A
- Gender: Male
Inclusion Criteria:
- Prostate cancer patients who have undergone diagnostic prostate biopsy in the past 9 months.
- Prostate biopsy tumor tissue (FFPR block) available for processing
- Age 18 years or older
- PSA <20 ng/ml
- Grade Group (GG) 1 cancer with > 2 biopsy cores involved with cancer OR GG2 cancer
- Ability to understand and the willingness to sign a written informed consent. A subject's legally acceptable representative may sign the consent form.
Exclusion Criteria:
- Clinical (on digital rectal exam) or radiographic evidence (if MRI performed) of T3 disease
- Nodal or metastatic prostate cancer (if staging imaging performed)
- Prior prostate cancer treatment, including prostatectomy, radiation therapy, or hormone therapy.
- Prior prostate gene expression classier testing
View trial on ClinicalTrials.gov